<DOC>
	<DOCNO>NCT00426439</DOCNO>
	<brief_summary>This study evaluate efficacy treatment artemether-lumefantrine compare chloroquine dose 50 mg/kg treatment malaria child Guinea-Bissau . The genetic basis parasite develop resistance examine . Children come one Health Centres symptom malaria positive malaria test include . The child follow weekly day 70 . In case reappearance parasite child re-treated opposite study drug .</brief_summary>
	<brief_title>Chloroquine Coartem Treatment Symptomatic Children With Plasmodium Falciparum Guinea Bissau</brief_title>
	<detailed_description>This study compare treatment uncomplicated malaria child Guinea-Bissau artemether-lumefantrine ( Coartem ) treatment chloroquine 50 mg/kg . Furthermore , genetic basis anti-malarial resistance Guinea-Bissau study analyze specific single nucleotide polymorphism pfcrt pfmdr1 blood sample vivo trial . We also intend study whether recent report chloroquine sensitive parasite select recrudescence Coartem confirm Bissau . Following consent participate , child visit one Health Centres study area mono-infection Plasmodium falciparum block-randomization allocate one treatment group . The treatment give supervise one health worker malaria film take day 2 3 . The child visit malaria film obtain weekly day 70 . On day seven , 100 microliter capillary blood drawn analyse analyse drug concentration whole blood . On inclusion whenever child recurrent parasitaemia , filter-paper blood-sample collect later PCR analysis . On day inclusion , day 42 day 70 haemoglobin level measure . If parasite reappear 50 % least 40 child one treatment group treatment arm terminate . During study parent recommend bring child health centre case illness . Participating child examine treated free charge . The opposite study drug use re-treatment child case recrudescence , child follow previously plan . The result study could use plan recommendation treatment malaria Guinea-Bissau . It provide National Malaria Programme information efficacy Coartem implement .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Children present one health centre study area Symptoms suggestive malaria At least 20 P.falciparum parasite per 200 leucocyte Living study area ( enable followup ) Danger sign By responsible doctor evaluate need transfer national hospital inpatient Previous idiosyncratic reaction study drug</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>malaria</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>child</keyword>
	<keyword>Guinea-Bissau</keyword>
	<keyword>artemether</keyword>
	<keyword>lumefantrine</keyword>
	<keyword>chloroquine</keyword>
	<keyword>Coartem</keyword>
</DOC>